Davion Jean-Baptiste, Cambron M, Duhin E, Chouraki A, Lacour A, Labauge P, Carra C, Ayrignac X, Vermersch P
Univ. Lille, INSERM, CHU Lille, U995, LIRIC, Lille International Research Inflammation Center, 59000, Lille, France.
Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
J Neurol. 2016 Jul;263(7):1361-3. doi: 10.1007/s00415-016-8144-x. Epub 2016 May 9.
We report two cases of primary progressive multiple sclerosis (PPMS) included in the INFORMS cohort, experiencing a relapse related to a single MRI gadolinium-enhancing lesion 3 months after fingolimod withdrawal. These two patients share similarities with relapsing-remitting multiple sclerosis cases described in the same situation, suggesting that the initiating process of the active demyelinating plaques is also present in PPMS, even without relapses, but may be triggered as fingolimod is withdrawn. Although the results of the INFORMS study suggest that fingolimod may not slow down the progression, some PPMS patients might still benefit from a disease-modifying treatment.
我们报告了纳入INFORMS队列的2例原发性进行性多发性硬化症(PPMS)患者,在停用芬戈莫德3个月后出现与单个MRI钆增强病灶相关的复发。这两名患者与在相同情况下描述的复发缓解型多发性硬化症病例有相似之处,表明即使没有复发,PPMS中也存在活动性脱髓鞘斑块的起始过程,但可能在停用芬戈莫德时被触发。尽管INFORMS研究结果表明芬戈莫德可能不会减缓疾病进展,但一些PPMS患者仍可能从疾病修饰治疗中获益。